WID Researchers Collaborate on UW2020 Projects
Researchers at the Wisconsin Institute for Discovery are co-Principal Investigators and co-Investigators on four UW2020: WARF Discovery Initiative projects.
WID researchers are engaged in cancer research from many different perspectives, including precision medicine, immunotherapy development, epigenic inquiry, and several omics-related angles. With a focus on Healthy People, WID is committed to working with its campus partners to understand and treat cancer more effectively.
Researchers at the Wisconsin Institute for Discovery are co-Principal Investigators and co-Investigators on four UW2020: WARF Discovery Initiative projects.
Peter Lewis and his research group at WID study how mutations in DNA-organizing histone proteins lead to cancer development.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
Mark Klein and Peter Lewis were recognized for their cancer research awards from The Ride, sponsored by the UW Carbone Cancer Center, at a recent Wisconsin Men’s Hockey game.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
Working to understand the fundamental mechanisms of chromatin-based gene regulation. The lab studies how various chromatin factors are recruited to chromatin to “read” and ‘translate” epigenetic information into differential gene expression patterns under normal growth and development as well as stress conditions.
By bringing together stem cell biology, genome engineering, and biomaterials expertise, the Saha lab generates new tools for use with human-induced pluripotent stem cells to ask unique questions about human biology and disease.
The Ashton Group is working to understand, model, and recapitulate in vitro the instructive signals utilized by human embryos to pattern tissue-specific differentiation of pluripotent stem cells, and apply this knowledge towards the rational design of tissue engineered scaffolds and other regenerative therapeutic strategies.
The Multi-Omics Hub will focus on the use of big data about the genes, microorganisms, and metabolites to understand biological systems. WID’s expertise makes it an ideal home for the Epigenetics Initiative for the large campus community that studies the epigenome, and as such WID will organize meetings, seminars, mutli-PI …
Kris Saha with colleagues David Beebe and Christian Capitini aim to develop improved methods for making CAR T-Cells with a two-year grant from the NSF.
Epigenetics researcher Peter Lewis has linked a histone mutation to a rare pediatric bone cancer, an important step in understanding and treating more common cancers.
The Epigenetics theme at WID is putting mass spectrometry to use in new ways with specialized workflows designed to uncover the mysteries of chromatin.
Short circuiting tumors via Epigenetics drives Lewis Lab’s research.
Xuehua Zhong, Assistant Professor in WID’s Epigenetics Theme studies the epigenetic connections mammals share with plants.
Through an Environmental Protection Agency initiative, WID researchers are playing a key role in learning how toxins impact human health and the environment.
Rupa Sridharan, Assistant Professor of Cell and Regenerative Biology at Wisconsin Institute for Discovery explains how she increased reprogramming efficiency to get pluripotent stem cells.